GREENWOOD CAPITAL ASSOCIATES LLC PCRX — PACIRA BIOSCIENCES INC

Ownership history in GREENWOOD CAPITAL ASSOCIATES LLC  ·  4 quarters on record

AI Ownership Summary

GREENWOOD CAPITAL ASSOCIATES LLC reported PACIRA BIOSCIENCES INC (PCRX) in 4 quarterly 13F filings from 2025 Q2 through 2026 Q1. Peak portfolio weight reached 0.06% in 2026 Q1. The latest visible filing shows PCRX at 0.06% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings.

What this PCRX ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was GREENWOOD CAPITAL ASSOCIATES LLC's position in PACIRA BIOSCIENCES INC, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2026 Q1

PCRX was reported at 0.06% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
0.06% in 2026 Q1

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2025 Q2 to 2026 Q1

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

PCRX stock page GREENWOOD CAPITAL ASSOCIATES LLC fund profile GREENWOOD CAPITAL ASSOCIATES LLC full holdings
How GREENWOOD CAPITAL ASSOCIATES LLC held PCRX — position size vs. price
% of Fund (quarterly)    PCRX price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 4 quarters  ▾
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2026 Q1 ADDED — — — 22,795 +3,471 +18.0% 0.06% $515K 2026-04-29 $25.14
2025 Q4 ADDED — — — 19,324 +4,426 +29.7% 0.05% $500K 2026-01-26 $20.50
2025 Q3 ADDED — — — 14,898 +1,742 +13.2% 0.04% $384K 2025-10-16 $22.77
2025 Q2 INITIATED — — — 13,156 — — 0.04% $314K 2025-07-21 $22.17

🏢 Other funds also holding PCRX

As of 2026 Q1 — sorted by position size

Doma Perpetual Capital Management LLC 16.86% Gagnon Advisors, LLC 3Y 7Y 5.86% GAGNON SECURITIES LLC 3Y 7Y 3.22% Bridge City Capital, LLC 3Y 7Y 2.52% Lion Point Capital, LP 3Y 7Y 1.82% EASTERLY INVESTMENT PARTNERS LLC 3Y 7Y 0.59% Phocas Financial Corp. 3Y 7Y 0.41% Three Seasons Wealth, LLC 0.38% MILESTONE ASSET MANAGEMENT, LLC 3Y 0.25% Hillsdale Investment Management Inc. 3Y 7Y 0.2%

FAQ About GREENWOOD CAPITAL ASSOCIATES LLC and PCRX

These are the practical questions this page is built to answer before you even open the full history table.

How long has GREENWOOD CAPITAL ASSOCIATES LLC reported owning PCRX?

GREENWOOD CAPITAL ASSOCIATES LLC reported PCRX across 4 quarterly 13F filings, from 2025 Q2 through 2026 Q1.

What was the largest reported PCRX position in GREENWOOD CAPITAL ASSOCIATES LLC's portfolio?

The largest reported portfolio weight for PCRX was 0.06% in 2026 Q1.

What is the latest reported PCRX position on this page?

The most recent filing on this page is 2026 Q1, when GREENWOOD CAPITAL ASSOCIATES LLC reported 22,795 shares, equal to 0.06% of portfolio, with an estimated market value of $515K.

What does the chart on this PCRX ownership page compare?

The chart compares GREENWOOD CAPITAL ASSOCIATES LLC's quarterly PCRX portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

How well did GREENWOOD CAPITAL ASSOCIATES LLC time their PCRX position?

Based on 13F filing dates vs. subsequent PCRX price moves, GREENWOOD CAPITAL ASSOCIATES LLC correctly timed 2 out of 3 reported position changes (67%). The annualised alpha on PCRX relative to SPY over the holding period was -0.8%.

← Back to GREENWOOD CAPITAL ASSOCIATES LLC Holdings